Skip to main content

Table 1 The clinical data of eight children with FCD type II

From: Upregulation of HMGB1-TLR4 inflammatory pathway in focal cortical dysplasia type II

Case ID 1 2 3 4 5 6 7 8
Gender Female Male Male Male Female Female Male Female
Age of onset 6 months 1 year 40 days 3 years 7 months 4 months 6 months 1 year and 10 months
Seizure type FS FS FS FS FS Spasm FS, atypical absence FS
Seizure frequency 10/day 1–2/day 2–10/day 1/week 1–4/day 3–4/day 2–4/day 3–10+/day
Status epilepticus None None None None None None EPC None
Antiepileptic drugs VPA, LEV, TPM, VGB OXC, LTG, PB, VPA, TPM, CZP, LEV VPA, OXC, TPM, PB, LEV, VGB LEV, CBZ, LTG, VPA, TPM VPA, OXC, PB, LTG, LEV, TPM VPA, TPM, OXC VPA, LEV, CZP, OXC VPA, OXC, TPM, LTG, NZP
Age of operation 1 year and 2 months 7 years and 3 months 2 years 4 years and 2 months 3 years and 6 months 1 year and 2 months 7 years and 3 months 13 years
Location of FCD Left temporal Right parietal Left parietal Left frontal Left central Right frontal Right frontal Right temporal
Pathological type of FCD FCD IIa FCD IIa FCD IIa FCD IIb FCD IIb FCD IIb FCD IIb FCD IIb
  1. VPA valproate, CBZ carbamazepine, OXC oxcarbazepine, PB phenobarbital, TPM topiramate, LEV levetiracetam, LTG lamotrigine, CZP clonazepam, NZP nitrazepam, VGB vigabatrin, FS focal seizures